PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy.

Abstract Recent studies have indicated that the C-reactive protein (CRP)/albumin (CRP/Alb) ratio is associated with clinical outcomes in patients with various carcinomas. However, no studies have explored the association between the ratio of CRP/Alb and clinical outcome of inoperable patients with nonsmall cell lung cancers (NSCLCs). We examined the prognostic impact of CRP/Alb ratio on 165 stage IV NSCLC receiving palliative chemotherapy. The optimal cutoff level of CRP/Alb ratio was set at 0.195. The median follow-up time was 9 months (range, 1-74 months). On univariate analysis, high CRP/Alb ratio (≥0.195) was correlated (P < .001) with poorer overall survival (OS). Subgroup analysis of adenocarcinoma showed that CRP/Alb ratio was significantly (P < .001) associated with OS. Multivariate analysis showed that CRP/Alb ratio was an independent prognostic factor for OS (hazard ratio: 2.227, P = .001). Subgroup analysis revealed that the CRP/Alb ratio had a significant (P = .001) prognostic impact on adenocarcinoma patients receiving platinum chemotherapy. Elevated CRP/Alb ratio was significantly associated with male gender (P = .002) and smoking history (P = .009). The results of this study suggest that the CRP/Alb ratio might be used as a simple, inexpensive, and independent prognostic factor for OS of patients with advanced lung adenocarcinomas receiving platinum chemotherapy.
PMID
Related Publications

The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer.

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer.

Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma.

Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.

Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28489774
OWN - NLM
STAT- MEDLINE
DA  - 20170510
DCOM- 20170612
LR  - 20170612
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 19
DP  - 2017 May
TI  - Prognostic impact of C-reactive protein/albumin ratio on the overall survival of 
      patients with advanced nonsmall cell lung cancers receiving palliative
      chemotherapy.
PG  - e6848
LID - 10.1097/MD.0000000000006848 [doi]
AB  - Recent studies have indicated that the C-reactive protein (CRP)/albumin (CRP/Alb)
      ratio is associated with clinical outcomes in patients with various carcinomas.
      However, no studies have explored the association between the ratio of CRP/Alb
      and clinical outcome of inoperable patients with nonsmall cell lung cancers
      (NSCLCs). We examined the prognostic impact of CRP/Alb ratio on 165 stage IV
      NSCLC receiving palliative chemotherapy. The optimal cutoff level of CRP/Alb
      ratio was set at 0.195. The median follow-up time was 9 months (range, 1-74
      months). On univariate analysis, high CRP/Alb ratio (&gt;/=0.195) was correlated (P 
      &lt; .001) with poorer overall survival (OS). Subgroup analysis of adenocarcinoma
      showed that CRP/Alb ratio was significantly (P &lt; .001) associated with OS.
      Multivariate analysis showed that CRP/Alb ratio was an independent prognostic
      factor for OS (hazard ratio: 2.227, P = .001). Subgroup analysis revealed that
      the CRP/Alb ratio had a significant (P = .001) prognostic impact on
      adenocarcinoma patients receiving platinum chemotherapy. Elevated CRP/Alb ratio
      was significantly associated with male gender (P = .002) and smoking history (P =
      .009). The results of this study suggest that the CRP/Alb ratio might be used as 
      a simple, inexpensive, and independent prognostic factor for OS of patients with 
      advanced lung adenocarcinomas receiving platinum chemotherapy.
FAU - Koh, Young W
AU  - Koh YW
AD  - aDepartment of Pathology bDepartment of Hematology-Oncology, Ajou University
      School of Medicine, Suwon, Republic of Korea.
FAU - Lee, Hyun W
AU  - Lee HW
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Platinum Compounds)
RN  - 0 (Serum Albumin)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/blood
MH  - C-Reactive Protein/*analysis
MH  - Carcinoma, Non-Small-Cell Lung/*blood/*drug therapy/mortality/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*blood/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Palliative Care
MH  - Platinum Compounds/therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - Serum Albumin/*analysis
MH  - Sex Factors
MH  - Smoking/blood
PMC - PMC5428608
EDAT- 2017/05/11 06:00
MHDA- 2017/06/13 06:00
CRDT- 2017/05/11 06:00
AID - 10.1097/MD.0000000000006848 [doi]
AID - 00005792-201705120-00041 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 May;96(19):e6848. doi: 10.1097/MD.0000000000006848.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>